HASTINGS DAVID C 4
4 · Arbutus Biopharma Corp · Filed Feb 5, 2025
Insider Transaction Report
Form 4
HASTINGS DAVID C
Chief Financial Officer
Transactions
- Sale
Common Shares
2025-02-04$3.28/sh−22,183$72,827→ 159,724 total
Footnotes (1)
- [F1]Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on March 6, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of previous grants of restricted stock units.